Enanta Pharmaceuticals

Glycopep is engaged in the synthesis and development of unique chemicals and resin products to support drug discovery. Glycopep is providing custom synthesis to academic institutions and pharmaceutical/biotech companies.

Trana Discovery, a drug discovery technology company, aims to help its partners find classes of drugs for the treatment of serious viral, fungal, and bacterial infectious diseases. The technology identifies compounds that work through a mechanism of action: inhibition of the target pathogen's ability to use transfer RNA (tRNA) essential for protein synthesis or replication. The use of Trana Discovery technology can unlock the value " scientific, human, and financial " hidden in drug compound libraries, expedite the discovery of drugs, and provide opportunities for exclusive rights to drug classes.

Aquapharm, founded in 2000, is a marine natural products company that uses marine bacteria, a very large untapped reservoir of natural products, and fungi to produce and commercialise functional food compounds and pharmaceuticals. The STF invested as part of a £1.9m funding round to develop Aquapharm's anti-microbial drug discovery business and to conduct pilot-scale manufacture and apply for Food status from the EU and FDA to allow sales into European and US markets.

Active Pass is a Canadian biotechnology company that is engaging in genomic-based drug discovery and is developing drugs that inhibit ABC transporters. ABC or (ATP binding cassette) is a term that describes the interconnected group of molecular engines or pumps that function as a transportation system which moves compounds across the biological membranes. These ABCs are very closely associated with human diseases like Alzheimer's disease, diabetes, asthma, and hypertension. The Active Pass management team is an accomplished group with experience in many aspects of drug discovery and development. Besides employing full time pharmaceutical development professionals, Active Pass has made wise use of a group of several key partnerships with different pharmaceutical groups. The company cultivates these partnerships in order to access new capabilities or expertise to advance the company's own technologies. More specifically, these partnerships include the Vaccines and Infectious Diseases Organization as well as the National Institute of Health). The company hopes to add new personnel to cover emerging areas of emphasis like clinical and regulatory affairs, business development and finance as they grow.

AureoGen is a research-based biotech company with a focus on discovery and production of commercially and clinically important cyclic peptide-based drugs, through genetic engineering of cyclic peptide producing organisms (as an alternative to complex and expensive synthetic chemistry methods). AureoGen's business is centered on generating intellectual property, both through discovery of genes, molecules and organisms and through development of technology and engineered organisms.

ProFoldin Protein Folding Services is committed to providing professional services and research tools to academic institutes, biotech and pharmaceutical industries in the area of protein sciences. One of the company's focus area is to help the company's customers to make active proteins from inactive ones, a process called protein folding. ProFoldin aims to provide protein folding columns and reagents and performs customer protein folding services.